Last update March 24, 2019
Incompatible
We do not have alternatives for : 3-(2-Chloroethyl)-2-(2-chloroethylamino)perhydro-1,3,2-oxazaphosphorinane 2-oxide .
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
: 3-(2-Chloroethyl)-2-(2-chloroethylamino)perhydro-1,3,2-oxazaphosphorinane 2-oxide is Ifosfamide in Chemical name.
Is written in other languages:: 3-(2-Chloroethyl)-2-(2-chloroethylamino)perhydro-1,3,2-oxazaphosphorinane 2-oxide is also known as
: 3-(2-Chloroethyl)-2-(2-chloroethylamino)perhydro-1,3,2-oxazaphosphorinane 2-oxide belongs to this group or family:
Main tradenames from several countries containing : 3-(2-Chloroethyl)-2-(2-chloroethylamino)perhydro-1,3,2-oxazaphosphorinane 2-oxide in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 100 | % |
Molecular weight | 261 | daltons |
Protein Binding | 20 | % |
VD | 0.64 - 0.72 | l/Kg |
pKa | 13.24 | - |
Tmax | 1 | hours |
T½ | 4 - 15 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
An alkylating agent from the group of nitrogen mustards with similar properties to cyclophosphamide, used in treatment of tumors of the cervix, lung, ovary, testicles and thymus; and in sarcomas and lymphomas.
Intravenous administration for 3-5 days and intervals of 2 to 4 weeks.
Since the last update we have not found published data on its excretion in breastmilk.
The manufacturer claims that it is excreted in breastmilk but without specific data or associated publications (Baxter 2015, Kemex 2015).
Pharmacokinetics show that after 3 elimination half-lives (T½) 87.5% of the drug is eliminated from the body; after 4 T½ it is 94%, after 5 T½, 96.9%, after 6 T½, 98.4% and after 7 T½ it is 99%. From 7 T½ the plasmatic concentrations of drug in the body are negligible. In general, a period of at least five half-lives can be considered a safe waiting period before breastfeeding again (Anderson 2016).
Taking the longest published T½ of all the active metabolites as a reference, these 5 T½ would correspond to 3 days. Due to major side effects, it would be advisable to wait 7 T½, which would correspond to 4.5 days. Meanwhile, express and discard milk from the breast regularly to maintain production.
Some authors recommend waiting 72 hours (4.8 T½) after the last dose to restart breastfeeding. (Hale 2017 p 478), and others only 48 hours (Schaefer 2007 p 743).
When it is possible to do so, milk detections of each patient to determine the total elimination of the drug would be the best indicator to resume breastfeeding between two cycles of chemotherapy.
During breast cancer treatment, breastfeeding must be interrupted due to potentially serious side effects for the infant. Chemotherapy does not affect milk production during or after treatment. Abrupt weaning can be psychologically traumatic for both the mother and the infant (Pistilli 2013). If the mother wishes, the production of milk can be maintained by regularly expressing milk from the breast, being able to return to breastfeeding in the periods in which no significant traces of the drug remain in the milk (Anderson 2016) or at the end of the treatment (Pistilli 2013).
Some chemotherapeutic agents with an antibiotic effect can alter the composition of the microbiota (bacterial set or bacterial flora) of the milk and the concentration of some of its components (Urbaniak 2014). This possibly occurs temporarily with subsequent recovery, although no harmful effects are assumed or have been reported in breastfed infants.
Women undergoing chemotherapy during pregnancy have lower rates of breastfeeding due to difficulties in breastfeeding (Stopenski 2017), needing more support to achieve it.
Given the strong evidence that exists regarding the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother who wishes to continue with breastfeeding (Koren 2013).
See below the information of these related products: